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Sleep promoters and insomnia
Hipnoindutores e insônia
Abst rac t
The purpose of this update article is to briefly describe the profile, clinical application and indication for use of some of the most
popular sedative and hypnotic compounds. Approximately two-thirds of all prescriptions for hypnotics are written for chronic
users. Benzodiazepines are among the most commonly prescribed drugs worldwide. Women, the elderly, psychiatric patients and
patients suffering from medical conditions are among chronic users of hypnotics. Zolpidem is currently the most widely prescribed
hypnotic in most countries. It appears to be safer than benzodazepines and might be an option for long-term and controlled ("as
needed") use. For insomnia patients in the USA and UK, antidepressants with sedative effects are also among the most frequently
prescribed drugs for sedation. In this study, the use and sedative effects of trazodone, mirtazapine, doxepin and amitriptyline are
described. The authors also examine the use and sleep-inducing properties of melatonin, as well as the rational use of sedative
antipsychotics for chronic insomnia, particularly in psychiatric patients. Finally, some phytotherapeutic compounds are discussed.
Keywords: Sleep initiation and maintenance disorders; Benzodiazepines; Melatonin; Antipsychotic agents; Hypnotics and sedatives;
Pyridines
Resumo
O objetivo deste artigo de atualização é o de descrever brevemente o perfil, a utilização clínica e a indicação de alguns dos
sedativos e compostos hipnóticos mais utilizados. Cerca de 2/3 de todas as prescrições hipnóticas vão para o uso crônico. Os
benzodiazepínicos estão entre as drogas mais prescritas mundialmente. As mulheres, os idosos e os pacientes psiquiátricos e
clínicos estão entre os usuários crônicos de hipnóticos. O Zolpidem é, atualmente, o hipnótico mais prescrito na maioria dos
países. Parece ser mais seguro em comparação aos benzodiazepínicos e poderiam ser uma opção para o uso de longo prazo e
controlado ("quando necessário"). Os antidepressivos sedativos encontram-se também entre as medicações mais prescritas para
sedação em pacientes com insônia nos EUA e no Reino Unido. São descritos efeito sedativo e uso de trazodona, mirtazapina,
doxepina e amitriptilina. Os autores também discutem o uso de melatonina e suas propriedades sedativas e o uso racional de
antipsicóticos sedativos para insônia crônica, em especial em pacientes psiquiátricos. Finalmente, alguns compostos fitoterápicos
são mencionados.
Descritores: Distúrbios do ínicio e da manutenção do sono; Benzodiazepinas; Melatonina; Agentes antipsicóticos; Hipnóticos e
sedativos; Piridinas
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I n t r oduc t i on
An ideal hypnotic should present, among others, the
following characteristics: 1) no effect on memory or cognition;
2) rapid absorption; 3) specific binding to the receptor; 4)
maintenance of physiological sleep; 5) no residual effects; 6)
optimal half-life; 7) no potential for abuse, tolerance or
dependence; 8) no active metabolites; 9) no respiratory
depression effect; 10) no interaction with alcohol or other
central nervous system depressants.1
Benzodiazepines: chronic use and ef fects on s leep
Benzodiazepines are among the most commonly consumed
drugs worldwide.2-3 In 2001, 6.96 billion daily doses of
benzodiazepines prescribed as hypnotics were consumed
worldwide; an impressive number if we consider that the world
population in that year was 6.135 billion people.4
The estimated rate of consumption of sleep-promoting drugs
among insomniacs in the city of São Paulo is approximately
20%, benzodiazepines being the most commonly consumed.5
Another study showed that, in the city of São Paulo, the highest
consumption of tranquilizers was registered among women
and among older individuals with some psychiatric morbidity.6
Of 4148 individuals evaluated in a study carried out in Great
Britain,7 7.7% were found to have used benzodiazepines within
the preceding year, the highest consumption being registered
among women.8 A total of 80% of patients started using
benzodiazepines daily after the first prescription, and 34% of
these patients were taking high doses (> 30 mg of diazepam).
Among in-patients, 70% present a history of alcohol abu-
se or abuse of other drugs, and 30% had some organic
brain disease. The following were the main reasons for
prescr ip t ion:  insomnia,  depress ion,  anx ie ty,  somat ic
complaints, pain symptoms9-10 and stress symptoms. Other
authors have reported that some known risk factors for
insomnia, such as being female, aging, working split shifts,
mental disorders or physical illness,11-12 are superimposed
on those for the use of benzodiazepines. It is notable that,
among the elderly, retirees or inactive individuals, as well
as widowers, are more predisposed to insomnia and the
ch ron i c  use  o f  benzod i a zep ines .  F ina l l y,  r ou t i ne
prescr ipt ion of benzodiazepines for minor psychiatr ic
disorders has been reported.13
However, some factors associated with dependence on
benzod iazep ines  and  the  w i thd rawa l  synd rome a re
observed: in the over-45 age bracket; consumption for more
than a year; drug pharmacology; factors intrinsic to the
patient; personality disorder; chronic dysphoria; chronic
insomnia; chronic physical illness; and previous history
of substance dependence.
Dependence on some benzodiazepines may develop within
days or weeks. The main withdrawal symptoms are generally
opposite to the expected therapeutic effects of the drug or cause
an intensified recurrence of the original symptoms. The term
"rebound" is used to describe the (transitory but more intense)
return of an original symptom, whereas "recurrence" (or
"relapse") presents the same pattern of symptom intensity and
presentation previously seen and is more persistent. "Addition",
which is rarer among individuals with primary insomnia,
implies recreational use, ingestion of high doses, long-term
use, etc. The withdrawal syndrome secondary to the
discontinuation of the substance consists, therefore, in the
onset of new signs and symptoms, as well as the worsening
of pre-existing ones.
Rebound, recurrence and withdrawal syndrome may be seen
in combination. All of the symptoms mentioned improved
within one to four weeks, except those of recurrence. Among
the symptoms related to the abrupt discontinuation of chronic
use are rebound anxiety, insomnia, rapid heart rate, increased
arterial pressure, sweats, nausea, vomiting, tremors, agitation,
diarrhea, convulsions, as well as psychiatric or neurological
symptoms. Some related mechanisms involve the severe loss
of GABAergic inhibition and sharp increase in the excitation
of the central nervous system. However, there are clear
differences among benzodiazepines in their capacity to produce
abstinence symptoms that may be independent of the
elimination half-life.14 In a recent study, lorazepam offered
more resistance to the relatively gradual discontinuation (15
days), in therapeutic doses equivalent to 10 mg of diazepam,
with an increase in the occurrence of symptoms.15
Studies with different benzodiazepines in therapeutic doses
show that long-term use (> 6 months) leads to a loss of efficacy
in the treatment of insomnia and a reduction in the quantity
of slow-wave sleep, as well as other alterations in the
electroencephalography (EEG) during sleep.15-16
In elderly patients, benzodiazepines must be prescribed with
caution since there have been reports of increased risk for
mortality due to chronic use.17 Other data show that more
than 50% of elderly patients would like to discontinue their
benzodiazepines.18 Therefore,  we can conclude that
benzodiazepines should be prescribed for short-term use for
the treatment of insomnia, and that it is necessary to develop
protocols to assist patients to stop using benzodiazepines.
However, a better understanding of use patterns and reasons
for use, the effects of chronic use and the cessation strategies
adopted by physicians and users is also necessary.
It is also known that benzodiazepines alter the sleep
architecture.15,19-20 The following are their main effects on sleep:
1) sedative-hypnotic, being involved in the decrease in sleep
latency, the increase in total sleep time and the decrease in
the number of awakenings; 2) alterations in the sleep
architecture, such as an increase in stage 2 non-rapid eye
movement (NREM) sleep, a decrease in slow-wave sleep, an
increase in latency for REM sleep, a decrease in the density
of rapid eye movements in REM sleep, and minor or no
alterations in the percentage of REM sleep. In addition,
benzodiazepines also alter the EEG during sleep, with a
decrease in delta activity, an increase in higher frequencies
(above 12 Hz) and an increase in s igma act iv i ty  or
benzodiazepine spindles (Table 1).
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Other hypnot ics and zo lp idem
In the 1980s and 1990s, new hypnot ics such as
cyclopyrrolones (zopiclone), imidazopyridines (zolpidem),
pyrazolopyrimidine (zaleplon) and imidazobenzodiazepines were
synthesized. Zolpidem and zaleplon have a similar mechanism.
Since they are more selective in the binding with the ϖ1
receptor, they are well tolerated and are hardly ever associated
with the appearance of tolerance and dependence caused by
long-term use. They differ, however, in the elimination half-
life, ultra-short (0.9 h) for zaleplon and short (2.4 h) for
zolpidem. Therefore, these drugs have been the treatment of
choice for insomnia in many countries. There are more studies
on zolpidem because this is a drug that has been used the
longest.21-22 Zolpidem and zaleplon are effective in decreasing
sleep onset latency, although zolpidem leads to an additional
increase in total sleep time. Neither compound presents resi-
dual effects during the day. However, zolpidem may increase
slow-wave sleep, which is generally decreased in insomnia
patients,23 without altering REM sleep or stage 2 NREM sleep.
There have been very few studies and zolpidem seems to be
contraindicated for children. Its elimination half-life may be
shortened in children, but there is a paucity of data on use in
this age bracket. However, there have been few studies
showing that it is safe for young adults,24 revealing preservation
of the normal curve of nocturnal growth hormone secretion.
Treating insomnia - which is generally chronic - is a
significant clinical problem. There is an apparent paradox
created by prescribing hypnotics for short-term use for a
chronic disorder. In fact, studies show that approximately two-
thirds (53 to 83%) of patients with chronic insomnia may
require long-term t reatment.25-27 Treatment wi th
benzodiazepines for a period longer than four weeks may
increase the risk of dependence.28 However, insomnia
symptoms vary in approximately two-thirds (49 to 83%) of
patients,29 and may occur on nonconsecutive nights in 72%
of cases. Studies of more than 6500 patients treated with a
10 mg/day dose of zolpidem for three to five nights per week
showed that insomnia was significantly reduced and that the
pattern of inappropriate nocturnal use was limited, without
the appearance of habituation, rebound insomnia, or any
significant residual daytime symptoms.30-33
Sedat ive ant idepressants
Some antidepressants present a significant sedative effect
that has been explored in the treatment of insomnia, especially
in insomnia concomitant with depression disorder. Trazodone,
mirtapazine, doxepin and amitriptyline have a stronger sedative
effect. Other antidepressants may also present some sedative
effect. However, some, rather than having a sedative effect,
may even cause insomnia as a side effect. Some epidemiological
data have shown that the use of antidepressants in the
treatment of insomnia has become more widespread due to
this potential for inducing sedation and alleviating anxiety (as
is the case for some compounds).34-35 The increased use of
sedative antidepressants in the treatment of chronic insomnia
may also be explained in part by their long-term use profile
and in part by the high incidence of depressive symptoms
among insomniacs.
Some mechanisms, such as antagonism of  type 1
histaminergic receptors, anticholinergic activity or a possible
influence on α-adrenoreceptors, have been proposed in order
to explain the sedative effect of these compounds. For some
antidepressants, tolerance to the sedative effect may develop
due to continued use.36 It is notable that the sedative effect
may occasionally occur with the use of much smaller do-
ses than those needed to produce an optimal antidepressant
effect, such as with more than 10 mg of amitriptyline, 15
mg of mirtazapine or 25 mg of trazodone. There have been
few studies, and there is still a need for guidelines on
appropriate therapeutic doses for the treatment of insomnia.
In general, antidepressants may cause either a slight or a
marked decrease in REM sleep, although their effects on
sleep var y. The higher the antidepressant potency in
increasing noradrenaline levels, the more REM may be
suppressed. In addition, sedative antidepressants may
increase total sleep time and decrease sleep onset latency.
A potential, although infrequent, side effect is increased
periodic movement of the limbs during sleep, especially
among tricyclic antidepressants.
Ant ipsycho t i cs
Antipsychotics are used in the treatment of almost all forms
of psychosis, including schizophrenia, schizoaffective disorders,
affective profiles concomitant with psychotic symptoms and
psychosis associated with organic mental diseases. They have
also been prescribed as anxiolytics or sedatives for patients at
high risk for developing benzodiazepine dependence, although
it is also necessary to take into account the risk of tardive
dyskinesia for some compounds.37 However, there is little
evidence, even empirical, that chronic insomnia should be
treated with antipsychotics.38
Despite being ever more frequently used, antipsychotics show
serious limitations: they are not efficacious for all patients,
they have significant side effects and even those patients who
initially responded well to treatment may continue to present
signs and symptoms of the disease.
Convent ional  or  f i rs t -generat ion ant ipsychot ics had
significant extrapyramidal side effects and, for this reason,
they were known as "neuroleptics". The discovery of new drugs
(atypical or second generation antipsychotics) that have fewer
motor side effects has led to the use of the term "antipsychotic"
rather than the term "neuroleptics".39 Among the older
antipsychotics, chlorpromazine and thioridazine have stronger
sedative effects than that of haloperidol. Clozapine may produce
deep and frequently prolonged sedation.40
Although antipsychotics have inconsistent effects on sleep
patterns, they tend to normalize the sleep alterations
characteristic of many psychoses. The capacity to prolong and
increase the effects of hypnotic and opioid drugs seems to be
related to the sedative potency of the antipsychotic agent and
is partially independent of the potency of its antipsychotic
effect. Therefore, more potent antipsychotic agents, which do
not cause sleepiness, also do not increase the sedation
produced by other drugs.41
Low tolerance to the side effects of antipsychotics limits the
dosage to be given to elderly individuals. Physicians should
use caution when prescribing agents of moderate and high
potency and should start with low, fractionated doses, in the
expectation that elderly patients will need lower doses than
those used for younger patients. Wiegand42 suggests using
antipsychotics in elderly patients when long-term treatment is
needed, especially when patients present abnormal nighttime
behavior. Wortelboer et al43 state that antipsychotics should
be used in elderly insomnia patients only when specifically
indicated, and that further studies are necessary in order to
endorse their use.
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Estivill at al44 used olanzapine in nine patients (6 females
and 3 males) with chronic insomnia. Single doses ranged
from 2.5 to 10 mg. Outcomes were described as positive in
eight patients, of whom five were given only the antipsychotic
and three were in polytherapy. The authors concluded that,
although the study sample was too small to demonstrate the
effectiveness of the drug in the treatment of chronic insomnia,
the clearly favorable outcomes in eight patients should
encourage research into the effects of these drugs.
Adler45 emphasized that ant ipsychot ics,  as wel l  as
antidepressants, are essential for the treatment of sleep
disorders accompanying some well-defined psychiatric
disorders. However, the author also stated that these drugs,
especially antidepressants, could be used as a second-line
medication in the treatment of primary insomnia. Other
situations in which antipsychotics are indicated could include
cases of severe or chronic insomnia, or both, that present
unsatisfactory responses to the treatments performed, when
there is risk of dependence on benzodiazepines or analogs.
Antipsychotics could also be prescribed during benzodiazepine
withdrawal. Nevertheless, due to the high incidence of side
effects, it is recommended that the risks and benefits of the
use of antipsychotics in the treatment of insomnia be carefully
evaluated. In summary, antipsychotics are not the medication
of choice in the treatment of primary chronic insomnia.1
Other  substances
Phytotherapeutic agents may be included in this group. There
are few data in the literature that quantify and prove the efficacy
of such substances in the treatment of insomnia. The majority
of the studies involve the use of Valeriana officinalis. The
valerenic acid and the valepotriates are the most commonly
described active principles, and the valerenic acid and the
chamomile extract may present, in vitro, an increase in the
GABAergic transmission.46-47 Valepotriates are principles whose
absorption is less stable. Valerenic acid decreases sleep latency,
as well as the amount of stage 1 NREM sleep, and increases
the amount of slow-wave sleep in insomniacs and in patients
suffering from sleep fragmentation.48-50
Side effects that may affect the gastrointestinal tract are
rare, and cardiovascular effects are even rarer. Further studies
of the use of passiflora, kava-kava and chamomile are
necessary. Valeriana off icinalis active extracts may be
prescribed for mild insomnia.
Me l a t on i n
Melatonin is the principal output of the pineal gland,
identified 2000 years ago. Although pineal calcification begins
early in life, there is no evidence that this process leads to
pinealocyte degeneration or a decrease in metabolic activity.
The main pineal hormone is melatonin, whose production
decreases with age.
The main route for melatonin synthesis is the retina, which
receives the light-dark impulses. Retinal afferents carry these
impulses to the suprachiasmatic tract, from which they continue
to the hypothalamic suprachiasmatic nucleus, which is the clock
that regulates circadian rhythms. Subsequently, the stimuli reach
the hypothalamus paraventricular nucleus, the spinal cord and
the superior cervical ganglion. The induction of melatonin
synthesis occurs after stimulation of β and α-noradrenergic
receptors located in the pinealocytes of the pineal gland. A total
of 85% of the melatonin synthesis results from the interaction
between noradrenaline and  β-receptors, whereas only 15%
results from the interaction of  α-adrenoreceptors.51 Immediately
after its synthesis, melatonin, or N-acetyl-5-methoxytryptamine,
is released into circulation and distributed to all of the organs
due to its liposolubility.52
Serum melatonin levels are low during the day and high
at night, reaching their peak between 2:00 and 4:00 am
and dropping before dawn. The physiological significance of
this rise in melatonin levels during the night is probably
related to several effects such as a decrease in body
temperature, changes in cerebral monoamine levels and
induction of sleepiness.53-55
Melatonin is linked to the light-dark cycle and, consequently,
to the wake-sleep cycle.52 Its therapeutic effect may be observed
in some sleep initiation and maintenance disorders, particularly
in the phase delay syndrome, a condition in which individuals
tend to go to sleep late and wake up late.56 In such cases, it is
important to set the time to wake up in the morning and subtract
approximately eight hours in order to determine the time to go
to bed. Melatonin may be administered up to three hours before
bedtime. The objective is to hasten sleep onset. Patients are
also encouraged to spend time in the sun or undergo
therapeutic phototherapy in the morning, and to do physical
exercises designed to inhibit melatonin production in the
morning and hasten its secretion at night. In contrasting
conditions, i.e. in patients with phase advancement, melatonin
should be administered in the morning. Melatonin may be
useful for treating other circadian rhythm disorders, such as
that occurring in split-shift workers and in individuals
experiencing jet lag.57
The mechanism by which melatonin exerts its hypnotic
influence has yet to be well elucidated. Some authors believe
that this effect results from the rise in indoleamine levels at
sleep onset, suggesting that endogenous melatonin participates
in the regulation of the wake-sleep cycle and leads to a cascade
of events that activate somnogenic structures, or even that
melatonin metabolites may have a hypnotic effect.58
Although some studies have also shown that melatonin has
beneficial effects on the treatment of insomnia, the results
are controversial since the melatonin effect depends on its
dosage and the time of day at which it is administered.59-64
Nave et al64 showed that 3 and 6 mg of melatonin administered
30 or 120 min prior to the beginning of the polysomnography
has the effect of reducing sleep onset latency. However,
Attenburrow et al65 found no differences in sleep latency when
lower doses of melatonin (0.3 and 1 mg) were used or when
melatonin was administered two hours before bedtime.
In a recent study, it was demonstrated that melatonin induces
sleep that is more consolidated. The authors compared the
results obtained from normal individuals taking 10 mg of
melatonin an hour before going to bed to those obtained from
those taking a placebo.66 Ten minutes of uninterrupted sleep
following the beginning of the exam was used as a criterion
for considering the onset of more consolidated sleep. In the
volunteers treated with melatonin, the onset of consolidated
sleep (10 consecutive minutes of sleep) was hastened.
Melatonin may be used to treat insomnia in elderly patients
and in patients who present, in addition to insomnia,
irregularities in the wake-sleep cycle.67-69 The identification of
melatonin metabolism and its effect on sleep has fostered
research into the synthesis of new pharmaceuticals, such as
ML-1 receptor agonists, e.g. ramelteon, for treating insomnia.70
Studies have demonstrated that melatonin also shows
oncostatic71 and antioxidant72 action as well as activating action
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on the immune system.73 To Michaud et al,74 melatonin would
have an inhibiting effect on dopamine production. They suggest
that this substance could be related to the worsening of the
restless legs syndrome. According to Cohen et al,75 melatonin
is involved in the genesis of histamine cephalgia as well as in
hypnic headache. The authors suggest that these types of
headaches could constitute a circadian rhythm disorder related
to REM sleep. According to some authors, acupuncture, yoga
and meditation increase melatonin secretion, thereby reducing
insomnia and anxiety.76-77
Agents with the potent ia l  for  inducing s leep under
s tudy for  c l in ica l  use
Indiplon, a novel pyrazolopyrimidine agent, has the in vivo
profile of an efficacious sedative-hypnotic, as well as presenting
high pharmacological specificity and in vitro allosteric
potentiation of GABA(A) receptors, with selectivity for alpha 1
subunit78 similar to that of zolpidem.
Studies suggest that ramelteon is a potent selective MT-1/
MT-2 receptor agonist and that it was more effective in
promoting and maintaining sleep than melatonin. However,
its potential for use in the treatment of sleep disorders has yet
to be invest igated.79 Eszopiclone is an isomer and a
cyclopyrrolone (like zopiclone) that presents, in studies,
potential for use in the symptomatic treatment of insomnia at
a dose of 3 mg.80
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